Where manual PGx reporting hits a ceiling

In many labs, PGx interpretation is still assembled by hand. A scientist cross-references each genotype against guidance, checks the patient’s medication list, drafts the narrative, and formats the report. It works at low volume, but the effort scales linearly: double the samples and you roughly double the hours. Turnaround stretches, and consistency depends on who happened to write the report.

SignalPGx moves interpretation into a structured pipeline. The lab runs genotyping and uploads results — VCF, CSV, Agena MassARRAY, or array data — and the platform grades each gene-drug interaction against CPIC guidelines, FDA pharmacogenomic labeling, DailyMed prescribing data, and DPWG, reconciled from 15+ curated sources. The manual cross-referencing that consumed analyst hours becomes an automated first pass.

Consistent reports from the first sample to the ten-thousandth

When interpretation is manual, variability creeps in. Two analysts can describe the same genotype differently, and the wording of a report can drift as staff change. That inconsistency is a quality problem long before it becomes a scaling problem.

An evidence-graded engine standardizes the output. Every report is built the same way, so results are:

• consistent

• standardized

• auditable

This removes the single-analyst bottleneck and keeps every report anchored to the same evidence base.

Review that scales with structure, not staff

Automation handles the first pass, but a clinical report still needs clinical judgment. The goal is not to remove the reviewer; it is to make review efficient enough that one medical director can sign out far more reports without cutting corners.

Every SignalPGx report is reviewed and signed out by the lab’s medical director. SignalAI assists interpretation and flags gene-drug interactions, but it never decides on its own — the clinician stays in control. Because the draft arrives complete, evidence-graded, and consistently formatted, the reviewer spends time on judgment rather than assembly. Structured review is what lets throughput grow without a matching growth in staff.

Keeping reports current without redoing the work

PGx evidence is not static. Guidelines are updated, and a patient’s medication list changes over time. In a manual shop, keeping older reports current would mean re-reading every case — work no team can absorb at volume.

Living Reports handle this automatically. When a guideline moves or a patient’s medications change, SignalPGx re-analyzes the affected reports and flags the ones that need attention, routing them back for a fresh medical-director review. Maintenance becomes a targeted queue instead of an open-ended manual burden.

Scaling shifts to platform capacity

Traditionally, growing a reporting line means adding analysts, more coordination, and more overhead.

With an automated pipeline, scaling shifts toward platform capacity.

The repetitive interpretation work is handled automatically, reports stay consistent, and delivery holds steady as volume climbs. Growth no longer depends on how many analysts you can hire.

decision = model.predict(input_data)
execute(decision)

Delivery and control at scale

Volume only helps if reports reach the clinician cleanly and the lab keeps control of its data. Manual delivery — emailing PDFs, re-keying results — does not scale any better than manual interpretation.

SignalPGx delivers into the EHR through FHIR R4, HL7 ORU, CDS Hooks, and SMART on FHIR, so as volume grows the lab can rely on:

1. branded reports delivered into the EHR

2. revocable Patient Passport QR links

3. a complete, auditable data trail

The platform stays multi-tenant, HIPAA- and GDPR-compliant, and runs on secured AWS with encryption in transit and at rest, RBAC, and strict tenant isolation, all fitting existing CLIA laboratory workflows.

Conclusion

Automation doesn’t replace the medical director — it restructures how a reporting line grows.

Labs that treat PGx reporting as a platform, not a headcount problem, gain a real advantage: faster turnaround, consistent evidence-graded reports, and the ability to grow volume without growing staff. Most labs go live in 5 to 7 days, with transparent per-report pricing that scales with volume and a pilot available to start.